Tags

Type your tag names separated by a space and hit enter

Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?
Expert Opin Investig Drugs. 2005 Mar; 14(3):339-42.EO

Authors+Show Affiliations

Doggrell Biomedical Communications, School of Biomedical Sciences, University of Queensland, QLD 4072, Australia. s_doggrell@yahoo.com

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

15833065

Citation

Doggrell, Sheila A.. "Will the New CB1 Cannabinoid Receptor Antagonist SR-147778 Have Advantages Over Rimonabant?" Expert Opinion On Investigational Drugs, vol. 14, no. 3, 2005, pp. 339-42.
Doggrell SA. Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant? Expert Opin Investig Drugs. 2005;14(3):339-42.
Doggrell, S. A. (2005). Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant? Expert Opinion On Investigational Drugs, 14(3), 339-42.
Doggrell SA. Will the New CB1 Cannabinoid Receptor Antagonist SR-147778 Have Advantages Over Rimonabant. Expert Opin Investig Drugs. 2005;14(3):339-42. PubMed PMID: 15833065.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant? A1 - Doggrell,Sheila A, PY - 2005/4/19/pubmed PY - 2006/4/14/medline PY - 2005/4/19/entrez SP - 339 EP - 42 JF - Expert opinion on investigational drugs JO - Expert Opin Investig Drugs VL - 14 IS - 3 SN - 1744-7658 UR - https://www.unboundmedicine.com/medline/citation/15833065/Will_the_new_CB1_cannabinoid_receptor_antagonist_SR_147778_have_advantages_over_rimonabant L2 - https://www.tandfonline.com/doi/full/10.1517/13543784.14.3.339 DB - PRIME DP - Unbound Medicine ER -